Novavax announced on Monday that it has filed for emergency use authorization of its COVID-19 vaccine for US adults, Reuters reported.
The filing is based on data provided to the US Food and Drug Administration last month and results of two late-stage trials in the United States, Mexico and the UK that showed the protein-based vaccine had an overall efficacy of about 90%, the company said.